A pharmaceutical composition containing benzimidazole for inhibiting the growth of cancers
CA 2217952 C · Owner: The Procter & Gamble Company · Inventors: Camden, James Berger
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
A pharmaceutical composition for the treatment of leukemia in mammals is disclosed. The particular fungicide used is a benzimidazole derivative of formula (I) wherein X is hydrogen, halogen alkyl of less than 7 carbon atoms , or alkoxy of less than 7 carbon atoms; n is a positive integer of less than 4; Y is hydrogen, chlorine, nitro, methyl or ethyl; and R is hydrogen or an alkyl group having from 1 to 8 carbon atoms, and R2 is 4-thiazolyl or NHCOOR1 wherein R1 is aliphatic hydrocarbon of less than 7 carbon atoms or the pharmaceutically acceptable inorganic or acid addition salts thereof. A pharmaceutical composition that inhibits the growth of tumors and cancers in mammals and can …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed April 11, 1996 and granted June 25, 2002. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended April 11, 2016.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by April 11, 2018.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.